Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hypomethylating Agent”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Very early researchLooking for participantsNCT07071155
What this trial is testing

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromesMyeloproliferative Overlap Neoplasms+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 18
Testing effectiveness (Phase 2)Looking for participantsNCT06191263
What this trial is testing

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia
Ryvu Therapeutics SA 98
Not applicableStudy completedNCT01041846
What this trial is testing

Dacogen Treatment in Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Janssen Korea, Ltd., Korea 103
Testing effectiveness (Phase 2)WithdrawnNCT04109690
What this trial is testing

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

Who this might be right for
MDS
Yale University
Early research (Phase 1)Temporarily pausedNCT06888323
What this trial is testing

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Who this might be right for
Refractory Myelodysplastic Syndrome
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT01893372
What this trial is testing

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 29
Testing effectiveness (Phase 2)Ended earlyNCT02992860
What this trial is testing

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

Who this might be right for
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
GWT-TUD GmbH 25
Testing effectiveness (Phase 2)Study completedNCT02550535
What this trial is testing

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Who this might be right for
Myelodysplastic Syndromes (MDS)Acute Myeloid Leukaemia (AML)
Cell Medica Ltd 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT06232655
What this trial is testing

Cladribine Venetoclax in Monocytic AML

Who this might be right for
Acute Myeloid Leukemia
University of Colorado, Denver 10
Testing effectiveness (Phase 2)Looking for participantsNCT04905810
What this trial is testing

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Who this might be right for
Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia
Brian Jonas 20
Testing effectiveness (Phase 2)Looking for participantsNCT05983276
What this trial is testing

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Who this might be right for
Ovarian Cancer
Loyola University 40
Early research (Phase 1)Study completedNCT00496444
What this trial is testing

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 69
Large-scale testing (Phase 3)Ended earlyNCT02562443
What this trial is testing

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Who this might be right for
Myelodysplastic SyndromeMDSRefractory Anemia With Excess Blasts+1 more
Traws Pharma, Inc. 372
Testing effectiveness (Phase 2)Ended earlyNCT03233724
What this trial is testing

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-Small Cell Lung Cancer+2 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Study completedNCT03672539
What this trial is testing

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT01980056
What this trial is testing

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Who this might be right for
Myelodysplastic Syndrome
Weill Medical College of Cornell University 10
Testing effectiveness (Phase 2)Study completedNCT03913455
What this trial is testing

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung CancerExtensive-stage Small Cell Lung Cancer
Shadia Jalal, MD 24
Large-scale testing (Phase 3)Looking for participantsNCT06465953
What this trial is testing

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Who this might be right for
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier 48
Testing effectiveness (Phase 2)Ended earlyNCT02546986
What this trial is testing

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Celgene 100
Testing effectiveness (Phase 2)Ended earlyNCT04851834
What this trial is testing

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Who this might be right for
Advanced Solid TumorPlatinum-Resistant Ovarian CancerPlatinum-Resistant Urothelial Carcinoma+1 more
Xennials Therapeutics Australia Pty Ltd 12
Next Page